



Published in final edited form as:

Nat Commun. 2013 ; 4: 2373. doi:10.1038/ncomms3373.

## Environmental Impact on Direct Neuronal Reprogramming *In Vivo* in the Adult Brain

Andrew Grande<sup>#1,3,5</sup>, Kyoko Sumiyoshi<sup>#1</sup>, Alejandro López-Juárez<sup>1</sup>, Jennifer Howard<sup>1</sup>, Bhuvanewari Sakthivel<sup>2</sup>, Bruce Aronow<sup>2</sup>, Kenneth Campbell<sup>1,3</sup>, and Masato Nakafuku<sup>1,3,\*</sup>

<sup>1</sup>Divisions of Developmental Biology, Cincinnati Children's Hospital Research Foundation, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA

<sup>2</sup>Division of Biomedical Informatics, Cincinnati Children's Hospital Research Foundation, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA

<sup>3</sup>Department of Neurosurgery, University of Cincinnati College of Medicine, 3125 Eden Avenue, Cincinnati, OH 45267-0521, USA

<sup>#</sup> These authors contributed equally to this work.

### Abstract

Direct reprogramming of non-neuronal cells to generate new neurons is a promising approach to repair damaged brains. Impact of the *in vivo* environment on neuronal reprogramming, however, is poorly understood. Here we show that regional differences and injury conditions have significant influence on the efficacy of reprogramming and subsequent survival of newly generated neurons in the adult rodent brain. A combination of local exposure to growth factors and retrovirus-mediated overexpression of the neurogenic transcription factor Neurogenin2 (Neurog2) can induce new neurons from non-neuronal cells in the adult neocortex and striatum where neuronal turnover is otherwise very limited. These two regions respond to growth factors and Neurog2 differently and instruct new neurons to exhibit distinct molecular phenotypes. Moreover, ischemic insult differentially affects differentiation of new neurons in these regions. These results demonstrate strong environmental impact on direct neuronal reprogramming *in vivo*.

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*To whom correspondence should be addressed: Masato Nakafuku M.D., Ph.D., Division of Developmental Biology, Cincinnati Children's Hospital Research Foundation, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, Phone, 513-636-9389; Fax, 513-636-4317, [masato.nakafuku@cchmc.org](mailto:masato.nakafuku@cchmc.org).

<sup>5</sup>Present Address: Department of Neurosurgery, University of Minnesota, Mayo Mail Code 96, 420 Delaware Street SE, Minneapolis, MN 55455.

### Competing Financial Interests

The authors declare no competing financial interests.

### Author Contributions

A.G., K.S., and M.N. designed and performed experiments, discussed results, and wrote the manuscript. A.L.-J, J.H., and K.C. provided reagents and helped analysis of data. B.S. and B.A. helped designs and data analysis of microarray experiments.

### Accession Codes

Microarray data have been deposited in Gene Expression Omnibus under the accession code GSE49194.

## Keywords

stem cell; regeneration; reprogramming; neurogenesis; ischemia; growth factor; gene therapy, brain injury

---

## Introduction

The discovery of induced pluripotent stem (iPS) cells has transformed our view on the cell type specificity in the animal body<sup>1</sup>. Combinatorial overexpression of just a few regulatory molecules can convert fully differentiated cells into most primitive pluripotent stem cells, demonstrating that cell type specification is reversible and reprogrammable<sup>1,2</sup>. Recent studies have further demonstrated that fully functional mature cells with particular cell types such as neurons and cardiac muscle cells can be directly generated *in vitro* from other cell types without passing through the stage of iPS cells<sup>3</sup>. Generation of tissue-specific stem/progenitor cells such as neural stem cells from fibroblasts has also been reported<sup>3</sup>. This direct reprogramming is a promising approach to obtain new functional cells and replace those lost to insults, the ultimate goal in regenerative medicine<sup>2,3</sup>. Most studies so far reported, however, have utilized *in vitro* culture to convert one cell type to the other, and some studies<sup>4-10</sup> have shown that direct reprogramming is also possible *in vivo* in adult organs, including the brain<sup>8-10</sup>. Yet, little is known thus far about the environmental influences on such *in vivo* reprogramming events. Cell reprogramming involves extensive epigenetic modifications<sup>2,3</sup>, and therefore, the complex *in vivo* environment is likely to have substantial influences on the process. Currently, little is known about the environmental impact on direct reprogramming.

In the adult mammalian brain, neurogenesis persists only in a few restricted regions, including the subventricular zone (SVZ) lining the lateral ventricle and the hippocampal dentate gyrus (DG)<sup>11</sup>. In these so-called neurogenic regions, adult neural stem/progenitor cells (here collectively called NPCs) serve as the source of new neurons<sup>11</sup>. Whether the production of new neurons also occurs in other regions of the intact brain remains controversial<sup>12,13</sup>. Nevertheless, recent studies have demonstrated that various insults induce new neurons in normally non-neurogenic regions<sup>14-16</sup>. These newly generated neurons in the injury site, however, are relatively small in number and survive only for a short period<sup>15,16</sup>. Given such a limited regenerative capacity, approaches alternative to the mobilization of endogenous NPCs need to be pursued, and cell reprogramming is one of such promising strategies.

In this study, we show that a combination of growth factors (GFs) and the neurogenic transcription factor (TF) Neurogenin2 (Neurog2)<sup>17</sup> induces new neurons from non-neuronal cells *in situ* in the adult rodent neocortex and striatum where neuronal turnover is otherwise restricted. We found that these two brain regions respond to GFs and Neurog2 differently and instruct new neurons to exhibit distinct phenotypes. Moreover, ischemic insult differentially modulates differentiation of new neurons in these regions. These results highlight strong environmental impact on direct neuronal reprogramming *in vivo*.

## Results

### In vivo manipulations using GFs and retroviruses

Previous studies have demonstrated that a combination of a few TFs can directly convert non-neuronal cells to functional neurons<sup>18-26</sup>. Although much attention has been focused on how these TFs modify the epigenetic landscape of target cells, an often-ignored condition is that reprogrammed cells are exposed to various growth stimuli and undergo multiple cell divisions in culture. Thus, we sought to test if an exposure to a high dose GFs augments cell reprogramming *in vivo*. As the means to genetically manipulate cells, we took advantage of the fact that retroviruses selectively infect proliferative cells, but not postmitotic neurons. To minimize false labeling of postmitotic cells and cell fusion between virus-infected cells and pre-existing neurons<sup>27</sup>, we used the non-pseudotyped vector pMXIG expressing enhanced green fluorescent protein (GFP)<sup>9,17</sup>.

We created stab wound at defined locations in the striatum and neocortex of the adult rat brain by focal injection of high-titer viruses, with or without a cocktail of fibroblast growth factor 2 (FGF2) and epidermal growth factor (EGF). Target areas were chosen to avoid labeling of endogenous NPCs and their progeny in the nearby SVZ and rostral migratory stream (RMS) (Fig. 1a-c). In fact, virus-infected cells were found as a cluster of GFP<sup>+</sup> cells confined to the area around the injected site at day 3 after infection (DAI-3) (Fig. 1d-k), and pre-labeling of NPCs with 5-bromo-2'-deoxyuridine (BrdU) before virus infection yielded few, if any, GFP/BrdU double-labeled cells in the SVZ or RSM (Supplementary Fig. S1). A subset of GFP-labeled cells expressed GFAP, NG2, nestin, and Olig2, known markers for NPCs and glial progenitors (Supplementary Fig. S2). We also identified RECA1<sup>+</sup> vascular endothelial cells and OX42<sup>+</sup> microglia/macrophages among GFP<sup>+</sup> cells. These populations, as a whole, however, comprised less than 50% of the total labeled cells. Importantly, no GFP<sup>+</sup> cells co-expressed neuronal markers in either the striatum or neocortex at DAI-3 (none among over 3,000 cells examined in each region). Thus, labeling of pre-existing neurons by GFP viruses was, if any occurred, below the detectable level. Even at later time points, few cells infected with control viruses alone expressed neuronal markers (2 GFP<sup>+</sup>/NeuN<sup>+</sup> cells out of 5,112 cells in the striatum and none out of 4,258 cells in the neocortex at DAI-14). These results are consistent with previous studies reporting limited neurogenesis after stab injury<sup>28,30</sup>.

### GFs and Neurog2 promote neuronal reprogramming in vivo

We then asked if GFs and Neurog2 promote neurogenesis. We observed no significant change in the spectrum of cell types among virus-infected cells in GF-treated animals, and few GFP<sup>+</sup> cells were Dcx<sup>+</sup> or NeuN<sup>+</sup> at DAI-3. Nonetheless, a small fraction of GFP<sup>+</sup> cells expressing Dcx and NeuN were detected at DAI-7 and DAI-14, respectively, in the striatum (Fig. 1l-m). No such cells were detected, however, in the GF-treated neocortex. Given this limited action of GFs, we next used Neurog2 viruses. In the striatum, Neurog2 viruses alone and Neurog2 together with GFs significantly increased GFP<sup>+</sup>/Dcx<sup>+</sup> and GFP<sup>+</sup>/NeuN<sup>+</sup> cells (Fig. 1o-s) (for quantification, see Fig. 2). Neuronal differentiation of GFP<sup>+</sup> cells was also demonstrated by co-labeling with TuJ1, MAP2, and HuC/D (Fig. 4a-e). Approximately three-fourth of these neuronal marker-positive GFP<sup>+</sup> cells ( $72 \pm 5\%$ ,  $n = 3$  animals) were

Neurog2<sup>+</sup> at DAI-7, but a much small fraction ( $17 \pm 4\%$ ) retained Neurog2 expression at DAI28 or later despite the sustained GFP expression, suggesting that the transgene is silenced over time.

In the neocortex, Neurog2 robustly increased GFP<sup>+</sup>/Dcx<sup>+</sup> cells at DAI-3 (Fig. 1t,u). Only a small fraction of GFP<sup>+</sup> cortical cells, however, expressed NeuN at DAI-14 (Fig. 1v,w). We tested two other neurogenic TFs, Pax6 and Ascl1. Consistent with a previous report<sup>8</sup>, a small percentage of cells infected with Pax6 viruses became Dcx<sup>+</sup> in the striatum and neocortex (0.1 and 0.5%, respectively) (Fig. 2a,b). Few GFP<sup>+</sup>/NeuN<sup>+</sup> cells, however, were detectable at later time points. Ascl1 did not promote neurogenesis at a detectable level in either regions, in agreement with previous studies<sup>9,31</sup> (Fig. 2a,b). Ascl1 alone is a potent inducer of neurogenesis in both NPCs<sup>32</sup> and fibroblasts *in vitro*<sup>18-26</sup>, and can induce new neurons *in vivo* in combination with other TFs<sup>10</sup>. Thus, its inability to induce new neurons *in vivo* suggests a significant difference between *in vivo* and *in vitro* conditions.

We next asked whether GFP<sup>+</sup> neurons are generated by cells that divide *in situ*. When BrdU was administered before stab wound, we did not detect any BrdU-labeled neurons around the stab wound (Supplementary Fig. S1). However, when BrdU was administered to animals twice a day for three days between DAI-0 and DAI-2,  $18 \pm 6\%$  of GFP<sup>+</sup>/MAP2<sup>+</sup> cells at DAI-7 and  $12 \pm 4\%$  of GFP<sup>+</sup>/NeuN<sup>+</sup> cells at DAI-14 ( $n = 3$  animals) were co-labeled with BrdU in the Neurog2/GF-treated striatum (Fig. 4c,d). BrdU-labeled neurons were also found in Neurog2/GF-treated neocortex at DAI-14 ( $8 \pm 3\%$  of GFP<sup>+</sup>/NeuN<sup>+</sup> cells examined,  $n = 3$ ). These results suggest that a significant fraction of GFP-labeled neurons originate from cells that proliferate after injury.

Several lines of evidence argue against the idea that GFP-labeled neurons result from infection of pre-existing neurons or cell fusion. First, it has been reported that NeuN<sup>+</sup> neurons fused with vesicular stomatitis virus coat protein G (VSVG) pseudotyped retrovirus-infected microglia/macrophages are barely detectable in the adult neocortex<sup>27</sup>. In fact, few cells infected with control viruses co-expressed Dcx or NeuN in our study. Second, such falsely labeled neurons, if ever exist, would emerge within a day after infection and do not survive longer than a week<sup>13,27</sup>. In our study, however, a relatively large number of labeled neurons emerged late after infection, and many of them remained weeks after labeling (see below). Finally, the aforementioned BrdU labeling demonstrates that GFP-labeled neurons derive from cells that divide after injury. Together, these data support the idea that GFs and Neurog2 induce new neurons from non-neuronal cells *in vivo*.

### Differential actions of GFs and Neurog2

To compare the environmental influence in the striatum and neocortex, we estimated the number of new neurons induced under various conditions based on the quantification of the total number of GFP<sup>+</sup> cells and the percentage of cells expressing neuronal markers among them at different time points (Fig. 3a and Supplementary Table S1). In the striatum, stab wound alone induced few GFP<sup>+</sup>/Dcx<sup>+</sup> or GFP<sup>+</sup>/NeuN<sup>+</sup> cells, but GF treatment produced a small, but significant number of labeled neurons (Fig. 3b-d). Although GFs slightly increased the total number of GFP<sup>+</sup> cells compared with control (1.2-fold), the net increases in the number of GFP-labeled neurons were much larger (> 20-fold), indicating that the

effect of GFs is not simply the expansion of virus-infected cells (Fig. 3d). Neurog2 stimulated the generation of GFP<sup>+</sup>/NeuN<sup>+</sup> cells despite a slight decrease in the number of infected cells (Fig. 3a,d). Moreover, the combination of GFs and Neurog2 led to a marked increase of GFP<sup>+</sup>/Dcx<sup>+</sup> and GFP<sup>+</sup>/NeuN<sup>+</sup> cells, demonstrating their synergistic actions. Importantly, GFP<sup>+</sup>/Dcx<sup>+</sup> cells emerged between DAI-3 and DAI-7, but disappeared by DAI-14 (Fig. 3b). By contrast, GFP<sup>+</sup>/NeuN<sup>+</sup> cells became detectable at DAI-7 onward, and over 60% of those detected at DAI-14 appeared to remain at DAI-84 (Fig. 3c). These results suggest that new neurons first emerge as Dcx<sup>+</sup> immature cells and subsequently become NeuN<sup>+</sup>, reinforcing the idea that GFs and Neurog2 promote the *de novo* production of neurons, not the survival of falsely labeled pre-existing neurons.

Unlike in the striatum, neither stab wound nor GFs alone induced new neurons in the neocortex (Fig. 3e). Although Neurog2 induced a large number of GFP<sup>+</sup>/Dcx<sup>+</sup> cells at DAI-3, only a few GFP<sup>+</sup>/NeuN<sup>+</sup> cells were found at DAI-14 (Fig. 3b,c,e). The addition of GFs increased GFP<sup>+</sup>/Dcx<sup>+</sup> cells, but again, only a few GFP<sup>+</sup>/NeuN<sup>+</sup> cells were found at DAI-28 (0.9% of GFP<sup>+</sup>/Dcx<sup>+</sup> cells found at DAI-3) (Fig. 3e). Thus, the actions of GFs and Neurog2 differ in the neocortex and striatum, and the production and/or maturation of new neurons appears more restricted in the neocortex.

From the above data, we estimated the extent of neuronal replacement. Stab wound combined with GFs and Neurog2 viruses caused a loss of  $3,836 \pm 619$  and  $1,866 \pm 129$  neurons in the striatum and neocortex, respectively ( $n = 3$  animals). Thus, the estimated replacement rate was 4.6% in the striatum and 3.2% in the neocortex at DAI-28. Although these rates are not remarkable in light of neuronal replacement, they are comparable to those reported for other injury conditions<sup>15,16</sup>. Given the fact that GFP viruses infected only a small number of cells in a focal area in our study, the actual potential of neuronal replacement *in vivo*, if a large number of cells in a widespread region are targeted, could be much greater than this estimation.

### Region-specific differentiation of new neurons

We next examined the molecular phenotypes of newly generated neurons. GFP-labeled striatal neurons were found in both the patch and matrix compartments (Fig. 4a-c,h-p) and surrounded by synaptophysin<sup>+</sup> synaptic speckles similar to neighboring neurons (Fig. 4f,g). Many of them were immunopositive for  $\gamma$ -amino butyric acid (GABA) (76 cells/76 cells examined in 3 animals) and Isl1 (18 cells/36 cells), reminiscent of differentiating striatal projection neurons (Fig. 4h-m). Although Neurog2 drives differentiation programs of cortical neurons when robustly overexpressed in the developing ventral telencephalon<sup>33</sup>, it also supports the production of striatal neurons when expressed moderately<sup>34</sup>. One exceptional marker was DARPP32. Although many GFP<sup>+</sup>/NeuN<sup>+</sup> cells expressed DARPP32 in the control virus-infected striatum (22 cells/50 cells) (Fig. 4n-p), none of the Neurog2 virus-infected cells were DARPP32<sup>+</sup> (0/118 cells). Thus, Neurog2 appeared to bias the phenotype of new neurons toward DARPP32<sup>-</sup> cells. To examine the connectivity of these neurons, the axonal tracer FG was injected into the globus pallidus, one of the targets for striatal neurons at DAI-84. In these animals, punctuated FG labeling surrounded GFP<sup>+</sup>/NeuN<sup>+</sup> cells at DAI-91 (8 cells/19 cells examined) (Fig. 4z,a2). FG labeling was

predominantly associated with the soma (Fig. 4b2), demonstrating that labeling was due to retrograde labeling, but not passive diffusion.

In the neocortex, few GFP<sup>+</sup> neurons were found in control virus-infected animals, and therefore, we focused on GF/Neurog2-treated animals. We detected GFP<sup>+</sup>/NeuN<sup>+</sup> cells immunopositive for glutamate (Glu) (18 cells/18 cells), glutamate receptor subunits 2/3 (GluR2/3) (13 cells/13 cells), and Bhlhb5 (17 cells/29 cells) in multiple layers at DAI-28 (Fig. 4q-y). Unlike in the striatum, no GABA<sup>+</sup> GFP<sup>+</sup>/NeuN<sup>+</sup> cells were found in the neocortex. These features resembled those of glutamatergic cortical neurons. Neurog2 viruses and GFs induced GFP-labeled neurons with similar phenotypes in the frontal, parietal, and occipital areas (Supplementary Fig. S3). Thus, although induced by the same manipulations, new neurons exhibit distinct molecular phenotypes in different environments.

### Impact of ischemia on neuronal induction

In the above studies, stab wound was the underlying injury condition. We next examined how ischemic injury affects neuronal reprogramming. We used a model that produces localized damage in the antero-lateral neocortex, leaving the striatum and other regions largely intact (Fig. 5a,d,g,k)<sup>35</sup>. Ischemia induced expansion of Dcx<sup>+</sup> neurons in the SVZ beyond its normal boundary with the adjacent striatum<sup>15,16</sup> (Supplementary Fig. S4). To distinguish SVZ- and striatal parenchyma-derived neurons, we first labeled SVZ cells with BrdU before ischemia, and subsequently labeled parenchymal cells with GFP viruses at DAI-0 (see Supplementary Fig. S2a). Few GFP-labeled neurons were detected in the control virus-infected striatum, indicating that the impact of ischemia alone was minimum (Fig. 5o). Neurog2 viruses and GFs induced a cluster of GFP<sup>+</sup>/Dcx<sup>+</sup> and GFP<sup>+</sup>/NeuN<sup>+</sup> cells around the injection site, but not near the LV (Fig. 5b,c,e,f), and ischemia modestly increased these cells (Fig. 5o). None of these cells were co-labeled with BrdU (Fig. 5c,f), indicating that SVZ NPCs and virus-infected striatal cells generated new neurons at distinct locations.

New neurons were barely detectable in control virus-infected, non-ischemic neocortex (Fig. 5p). We found, however, a small number of GFP<sup>+</sup> cells expressing Dcx and NeuN in the ischemic cortex (Fig. 5h-i). Co-treatment with Neurog2 viruses and GFs induced a larger number of GFP<sup>+</sup> cells to express Dcx (1.5-fold) and NeuN (8.2-fold) (Fig. 5p). Moreover, more Dcx<sup>+</sup> cells appeared to proceed to NeuN<sup>+</sup> neurons between DAI-7 and DAI-14 after ischemia (5.1% versus 0.9%), suggesting that ischemia augments both the production and subsequent maturation/survival of new neurons. Interestingly, about a half of GFP<sup>+</sup>/NeuN<sup>+</sup> cells in control virus-infected neocortex were GABA<sup>+</sup> (12/23 cells), but none of them were Glu<sup>+</sup> (0/28 cells) or GluR2/3<sup>+</sup> (0/34 cells) (Fig. 5i). By contrast, all GFP<sup>+</sup>/NeuN<sup>+</sup> cells examined were Glu<sup>+</sup> (27/27 cells) and GluR2/3<sup>+</sup> (15/15 cells) in Neurog2 virus-treated animals (Fig. 5n). Thus, Neurog2 appeared to promote differentiation of glutamatergic neurons in the adult neocortex as in embryos<sup>33,34</sup>.

### GFs increase cells capable of forming neurospheres

Recent studies have shown that skin fibroblasts can be reprogrammed to become neurons<sup>18-26</sup>, as well as NPCs<sup>36-39</sup>. The aforementioned data also show that some GFP-labeled neurons originate from cells that divide *in situ*. Such dividing cells could be either

NPCs or other cell types. To test the former possibility, we asked if cells labeled with GFP viruses *in vivo* are capable of forming neurospheres, a hallmark of NPCs *in vitro*. We administered GFs and control viruses to adult rats, and subsequently isolated small pieces of tissue around the injection sites at DAI-3. In the presence of FGF2 and EGF,  $0.61 \pm 0.26\%$  of SVZ-derived cells formed neurospheres, whereas such cells were rare in the neocortex and striatum of uninjured brains ( $0.03 \pm 0.02\%$  and  $0.09 \pm 0.03\%$ , respectively) (Fig. 6a-j and Table 1). The content of sphere-forming cells in the corpus callosum, which has been reported to contain NPC-like cells<sup>40</sup>, was also extremely low ( $0.005 \pm 0.001\%$ ) (Fig. 6j). However, tissues that received stab wound and GFs yielded many more neurospheres than control as reported in previous studies<sup>28-30</sup> (Fig. 6c-e, Table 1). Most of these GFP<sup>+</sup> spheres were composed entirely of GFP<sup>+</sup> cells (355/362 striatum-derived spheres and 89/90 cortex-derived spheres examined) (Fig. 6a,b), and conversely, the rest of the spheres contained few, if any, GFP<sup>+</sup> cells, demonstrating the clonal expansion of GFP<sup>+</sup> neurospheres. After passage, these primary spheres formed secondary spheres composed of cells incorporating BrdU, indicating that they were proliferating *in vitro* (Fig. 6f-h). Moreover, the frequency of cells forming secondary spheres within primary spheres was comparable between the three regions (Fig. 6j). When these secondary neurospheres were induced to differentiate in monolayer, the percentage of TuJ1<sup>+</sup> neurons among total cells was also similar in the three cultures (Fig. 6i,m). The ratio of GFAP<sup>+</sup> astrocytes, however, was about two-fold higher in the SVZ-derived culture, and the cortical culture contained a higher percentage of O4<sup>+</sup> oligodendrocytes compared with the other two regions (Fig. 6k-m). These results support the idea that stab wound and GFs promotes the generation of NPC-like cells *in vivo*.

### Distinct gene expression profiles of NPC-like cells

We next isolated similar NPC-like cells from the adult mouse brain and characterized their properties by microarray-based gene expression profiling. Among 41,170 probes covering the mouse genome, we identified 3,781 probes representing 3,003 genes that gave more than a 5.0-fold higher hybridization signal with one or more of the adult neurosphere-forming cells compared with the whole brain (Fig. 7a). Clustering analyses of three independent samples demonstrated a reproducible gene expression profile of cells derived from each region (Fig. 7b). Among these genes, 1,558 genes were common between cells from all three regions, whereas 435 and 58 genes were uniquely enriched in neocortical and striatal cells, respectively (Fig. 7a).

Many genes commonly expressed in embryonic and adult NPCs encode TFs<sup>41</sup>. We thus focused our initial analysis on this class of genes. Neurospheres isolated from the dorsal and ventral forebrains of E14.5 embryos (vFB and dFB, respectively) were included for comparison. Some TFs were expressed at similar levels (less than 2-fold difference) across adult cells, which included Sox2, Emx2, Gsx2, and Ascl1 (Fig. 7c-f). Sox2 is ubiquitously expressed in undifferentiated progenitors, whereas Emx2 is expressed in a forebrain-specific manner during development<sup>40</sup>. Their expression thus reflects their common properties as NPCs with a forebrain identity. Although the expression of Gsx2 and Ascl1 is mostly confined in the vFB in embryos<sup>42</sup>, we detected similar expression levels of these TFs across the adult and embryonic cells. By contrast, Pax6 and Neurog2 were expressed in higher levels in neocortical cells than SVZ and striatal cells, whereas Six3 was expressed in an

opposite manner (Fig. 7g-i). These patterns mirror the difference between the embryonic dFB and vFB, the primordia of the adult neocortex and striatum, respectively<sup>42</sup>. We confirmed the expression of some of these TFs at the protein level by immunostaining (Supplementary Fig. S5). These results demonstrate that NPC-like cells induced in the adult neocortex and striatum exhibit distinct molecular profiles *in vitro*. Although we examined if GFP-labeled cells express any of these TFs in stab-wounded animals *in situ*, we could not find such cells. It could be that such cells exist only transiently or in small number, or manifest unique molecular phenotypes after expansion *in vitro*. Thus, the biological relevance of each of these genes in the context of *in vivo* reprogramming remains to be further investigated.

## Discussion

Recent studies have demonstrated that a variety of non-neuronal cells can be reprogrammed to become neurons and NPCs *in vitro*<sup>18-26,36-39,43-46</sup>. Other studies have also shown that fully differentiated cells acquire the properties of tissue-specific stem cells *in vivo* under certain circumstances<sup>4-7</sup>. In line with these emerging findings, we found that exposure to GFs and overexpression of the neurogenic TF Neurog2, in combination of stab wound, can induce new neurons in the adult neocortex and striatum where neuronal turnover is otherwise absent or extremely rare<sup>12,13</sup>. Stab wound or ischemia alone did not induce such neurogenesis at a significant level, indicating that GFs and Neurog2 exert unique actions to reprogram non-neuronal cells. *In vivo* treatment with GFs and Neurog2 also increased the frequency of cells that were capable of forming neurospheres *in vitro*, suggesting that the production of neurons occurs, at least in part, through the generation of NPC-like cells. Interestingly, such NPC-like cells derived from different regions exhibited distinct molecular profiles *in vitro*. Thus, reprogrammed cells in the adult brain appear to inherit distinct properties of the cells of their origin. Whether such differences are attributable to their intrinsic properties or the influence of their environment remains to be examined.

The retrovirus used in this study infected many different cell types *in vivo*, yet only a small fraction of infected cells were reprogrammed to become neurons. Thus, the identity of cells that retain a competency to become neurons in response to GFs and Neurog2 is currently unknown. Various cell types, including astrocytes and pericytes in the brain, have been shown to be reprogrammable to neurons and NPCs *in vitro*<sup>18-26,43-46</sup>. Recent studies also suggest that certain glial cells such as reactive astrocytes and NG2<sup>+</sup> glial progenitors exhibit a capacity for neurogenesis *in vitro*<sup>28-30</sup> and *in vivo*<sup>47,48</sup>. Thus, these glial cells may serve as the source of new neurons. In fact, a recent study has demonstrated the generation of new neurons by direct conversion of astrocytes in the striatum *in vivo*<sup>10</sup>. These cells, however, comprised a minor fraction of total virus-infected cells in our study. Thus, given the reported low efficiency of neuronal reprogramming of each of these cell types *in vitro*, it could be that GF/Neurog2-induced neurons originate from multiple non-neuronal cells rather than one specific cell type. Alternatively, the adult neocortex and striatum may contain cells that intrinsically retain the properties of NPCs but remain dormant in the intact brain. In this scenario, the action of GFs and Neurog2 is to mobilize them to differentiate into neurons. In fact, previous studies have reported the occurrence of such cells outside the known neurogenic niches<sup>28-30,49,50</sup>.



An important finding in this study is that the *in vivo* environment affects many aspects of neuronal reprogramming *in vivo*. In the striatum, GFs or Neurog2 alone induced a small, but significant number of new neurons after stab wound, and their combination further stimulated local neurogenesis. In the neocortex, however, Neurog2 alone induced a large number of immature neurons, but only a small number of mature neurons remained at later stages. A previous study has also shown that overexpression of Pax6 and a dominant-negative form of Olig2 induces immature, but not mature neurons in the adult neocortex<sup>8</sup>. Thus, neuronal reprogramming appears to be more restricted in the neocortex than in the striatum. Interestingly, both the production and subsequent maturation of new neurons were enhanced after focal ischemia in the neocortex. Thus, stab wound and ischemia modulate local neurogenesis in different manners. Our data have also demonstrated that the *in vivo* environment strongly influences the molecular phenotypes of newly generated neurons *in vivo*.

What mechanisms underlie these differences is currently unknown. It could be attributable to differences in the intrinsic properties of cells or environmental regulations, or both. Differential inflammatory and immune responses or expression of distinct GFs, cytokines, and morphogens could underlie the region- and injury-specific regulation of neurogenesis<sup>16,51</sup>. If reprogrammed neurons are to be utilized for brain repair, it is crucial to understand the nature of these environmental signals and their mechanisms of action. Whether new neurons generated in injured brains contribute to functional recovery also needs to be further investigated. Although our preliminary studies did not detect significant impact of neuronal reprogramming *in vivo* on behavioral recovery after stab wound or ischemic injury, it could be because of the relatively small number of new neurons induced by the method employed in this study. Yet, it is encouraging that recent studies have shown that exogenous NPC-derived or reprogrammed neurons, when transplanted in a large number, can be integrated into the existing circuitry and contribute to certain function, demonstrating that the adult mammalian brain is receptive to new neurons<sup>18-26,43-46,52-55</sup>. Further understanding of the environmental impact on neuronal reprogramming *in vivo* may lead to the development of new strategies to augment the latent regenerative potential of the adult brain.

## Methods

### Animals

Adult male Sprague-Dawley rats (10-12 weeks of age, 300-360 g) were used in all *in vivo* experiments. Adult male CD1 mice (10-12 weeks of age, 30-40 g) were used for gene expression profiling of neurospheres. All animal procedures were performed according to the guidelines of the Institutional Animal Care and Use Committee and the National Institute of Health.

### Retrovirus infection and other *in vivo* manipulations

High-titer solutions ( $2 \times 10^8$  colony forming unit/ml) of recombinant retroviruses pMXIG and its derivatives expressing Neurog2, Pax6, and Ascl1<sup>9,14,32</sup> were prepared with artificial cerebrospinal fluid (124 mM NaCl, 5 mM KCl, 1.3 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 26 mM

NaHCO<sub>3</sub>, and 10 mM D-glucose, with the pH adjusted to 7.2 using aeration with 95% O<sub>2</sub>–5%CO<sub>2</sub>) containing rat serum albumin (1 mg/ml, Sigma-Aldrich). In some experiments, the virus solution was supplemented with FGF2 (0.9 µg/ml; Peprotech) and EGF (0.9 µg/ml; Roche).

The virus solution was delivered into the brain through an infusion cannula with an external guide cannula (Plastic One) at a flow rate of 1 µl/min with an automated injection pump (BASi) attached to a stereotaxic injection device (Narishige, Tokyo, Japan)<sup>44</sup>. For injection into the striatum, the cannula was placed 0 mm anterior and 3.0 mm lateral from bregma, and the cannula tip was placed 4.0 mm deep from the skull surface. This stereotaxic coordinate targeted the middle of the dorsal aspect of the striatum of adult rats<sup>56</sup>. Injection into the frontal area of the neocortex was performed with the cannula placed 2.5 mm anterior and 2.0 mm lateral from bregma, and the depth was 2.0 mm. After injection, the cannula was left for additional 10 min before removing.

### **BrdU labeling**

To label proliferating cells in the brain, BrdU (150 mg/kg of body weight, Sigma-Aldrich) dissolved in 0.9% sterile saline was injected intraperitoneally in two different paradigms. In the pre-labeling paradigm, BrdU was administered to animals twice a day for three consecutive days, and subsequently viruses were injected into the brain 24 hours after the last BrdU injection. In the post-labeling experiments, the first administration of BrdU was performed 2 hours after virus injection, and subsequently repeated every 12 hours for three days.

### **Retrograde axonal tracing**

One µl of artificial cerebrospinal fluid containing 3% (w/v) FluoroGold (FG) was injected into the globus pallidus ipsilateral to the virus injection site<sup>57</sup>. The stereotaxic coordinates were 2.3 mm posterior and 4.0 mm lateral to bregma, and the cannula depth was 6.8 mm<sup>5</sup>. FG was injected 84 days after virus infection, and animals were sacrificed at day 91. Serial sections of the brain were examined to confirm that bulk labeling was confined to the globus pallidus without significant passive diffusion into adjacent regions.

### **Focal cortical ischemia**

Rats were anesthetized with isoflurane [2.0% (v/v)] and maintained at the lateral position with mechanical ventilation (1% isoflurane in a mixture of 30% O<sub>2</sub> and 70% N<sub>2</sub>O). The blood gas conditions were kept at the constant levels (PO<sub>2</sub>, 120±10 mm Hg; PCO<sub>2</sub>, 35±3 mm Hg) and the rectal and temporal muscle temperatures were maintained at 37.5±0.2C and 37.0±0.1C, respectively, throughout surgery. The distal branch of the middle cerebral artery (MCA) was exposed at its proximal trunk through the subtemporal approach, thermo-coagulated with a bipolar coagulator (MIZUHO Co., Ltd., Tokyo, Japan), and severed with a microscissor at the position just distal to the lenticulostriate branch. This occlusion causes localized damage in the dorso-lateral neocortex, whereas the rest of the neocortex and other brain regions remain mostly intact<sup>35</sup>. After surgery, animals were maintained on a heating blanket to prevent hypothermia until they began spontaneous movement, and subsequently

returned to their home cages and individually housed. For subsequent 3 days, animals were inspected daily to ensure that they had access to food and water.

### Histological analysis

For quantification of GFP- and BrdU-labeled cells, every 10 sections among serial coronal sections of the entire striatum (−0.3 to +1.6 mm from bregma, approximately 95 sections) or the anterior part of the neocortex (+3.2 to +4.7 mm from bregma, approximately 75 sections) were subjected to immunostaining. Among all animals examined, the maximum dispersion of GFP<sup>+</sup> cells was observed in an area of approximately 2.0 mm<sup>3</sup> in volume (antero-posterior, 1.0 mm; dorso-ventral, 1.0 mm; and medio-lateral 2.0 mm) in both the striatum and neocortex, but in most cases, they were confined to a smaller area (< 1.0 mm<sup>3</sup>). Fifty to 500 GFP<sup>+</sup> cells were detected per section depending on its distance from the injection site. The total number of GFP<sup>+</sup> cells and the percentage of cells double stained for specific markers were estimated in each manipulated animal, and the results are expressed as mean ± standard deviation (S.D.) of the data obtained from 3 to 4 independent animals. To validate the co-staining of multiple markers in single cells, samples were examined by confocal Z-sectioning at an interval of 1.0 mm using LSM-510 (Carl Zeiss). Only cells that appeared to retain the intact soma and nuclei within a given section, which was judged according to the staining pattern of GFP and BrdU, were counted. At least 100 or more double-labeled cells were observed using confocal microscope in representative sections from animals treated under different conditions. Quantification of the number and density of BrdU-labeled cells in the SVZ and parenchyma was performed using 4 representative coronal sections from each animal in which a cluster of GFP<sup>+</sup> cells were detected around the injection site. The SVZ was defined as the 100 µm-wide region lining the LV.

### Immunostaining

Animals were euthanised with CO<sub>2</sub> and fixed by intracardiac perfusion with 4% (w/v) paraformaldehyde (PFA; Acros Organics). Brains were collected and post-fixed with PFA for an additional 12 hours. Subsequently, the samples were cryoprotected with sucrose and embedded into OCT compound (Sakura Finetek U.S.A.). Twenty µm-thick sagittal or coronal sections were serially collected on slide glasses and subjected to immunostaining<sup>9,14</sup>. When staining was visualized with a colorimetric substrate for peroxidase (Pierce), sections were counter-stained with methylgreen (Sigma-Aldrich). Images were captured using the CCD camera Pixera Pro 600ES attached to the microscope BX-50 (Olympus). Images after staining with secondary antibodies conjugated with fluorescence probes were obtained with the Axiophoto2 (Carl Zeiss) equipped with the CCD camera C5810 (Hamamatsu Photonics) or with LSM-510 (Carl Zeiss). The antibodies used for immunostaining are listed in Supplementary Table S2.

### Neurosphere culture

One mm-thick serial coronal slices of brains were prepared using the rodent brain matrix (ASI Instruments). The striatum and dorso-frontal cortex were microdissected under the binocular microscope SV-11 (Carl Zeiss). Rat brain tissues were isolated from the slices encompassing approximately +3.5 to +2.0 mm from bregma for the neocortex and −0.5 to +1.5 mm for the striatum using the optic chiasm as an anatomical landmark<sup>5</sup>. For mouse

brains, slices encompassing approximately +1.4 to +0.0 mm from bregma were used<sup>58</sup>. In both cases, incisions were placed at least 0.5 mm away from the visible borders of the LV and corpus callosum to avoid contaminations of the adjacent white matter and periventricular tissue. A stripe of tissue lining the LV (approximately 100  $\mu\text{m}$ -thick) was collected as a specimen containing the SVZ. For gene expression profiling studies, the dorsal and ventral forebrains, which contain the embryonic primordia of the neocortex and striatum, respectively, were isolated from mouse embryos at embryonic day (E) E14.5<sup>59</sup>.

Dissociated single cells were seeded at a density of  $1 \times 10^4$  cells/ml in a growth medium [1:1 mixture of Dulbecco's modified Eagle's medium and F-12 medium (Invitrogen) supplemented with B-27 and N2 supplements (Invitrogen), 20 ng/ml FGF2, 20 ng/ml EGF, 20 ng/ml platelet-derived growth factor (Roche), 2  $\mu\text{g}$ /ml heparin sulfate (molecular mass of 3000; Sigma-Aldrich), 1 mg/ml bovine serum albumin (Sigma-Aldrich), and 100  $\mu\text{M}$  2-mercaptoethanol (Sigma-Aldrich)<sup>9,14,32</sup>. Culture dishes were coated with 20 mg/ml poly [2-hydroxy-ethyl methacrylate] (Sigma-Aldrich) to prevent cell attachment. At day 14 *in vitro* (DIV-14), the number of neurospheres with a diameter over 100  $\mu\text{m}$  was counted. Subsequently, these primary neurospheres were subjected to serial passages under the same conditions. BrdU (0.5  $\mu\text{M}$ ; Sigma-Aldrich) was added to the culture of secondary neurospheres for 3 days between DIV-14 and DIV-17 to detect dividing cells in neurospheres. In some experiments, brains that received retrovirus infection *in vivo* (see below) were subjected to neurosphere culture. The site of virus injection in coronal slices was identified under the microscope, and small piece of tissue around the injection site was removed. A portion of the sample was subjected to immunostaining for GFP, and the number of GFP<sup>+</sup> cells among total viable cells was quantified. The rest of the sample was subjected to neurosphere culture as described above.

To induce differentiation, primary or secondary neurospheres were seeded onto poly-D-lysine (PDL; 100  $\mu\text{g}$ /ml; Sigma-Aldrich)-coated 8-well chambers (Nalge Nunc), either as cell aggregates (approximately 20 spheres per well) or at a density of  $2 \times 10^4$  cells per well after dissociation. The resultant cells were further cultured in a growth medium without GFs. The cells were subjected to immunostaining for  $\beta$ -tubulin type III (TuJ1), glial fibrillary acidic protein (GFAP), and O4 at DAI-10. Immunoreactive cells were visualized with secondary antibodies conjugated with Alexa Fluor dyes (1:200; Invitrogen). To count cell numbers, cell nuclei were stained with 1  $\mu\text{g}$ /ml Hoechst 33258 (Invitrogen).

### Gene expression profiling

Secondary neurospheres derived from different brain regions were subjected to gene expression profiling studies using microarrays. Three sets of adult mouse brain-derived cells were obtained from independent culture experiments. Freshly isolated tissues and neurospheres derived from the dorsal and ventral forebrains of E14.5 mice were used for comparison. RNeasy mini kit (QIAGEN) was used for isolation and purification of total RNAs. The concentration of RNA was measured using RNA Assay Nanoprep Chip 6000 and Bioanalyzer (Agilent). To compare the expression profiles across the samples, Affymetrix GeneChip Mouse Genome 430 2.0 Array Platform (total 41,170 probes) was used, and the data were analyzed using Silicon Genetics GeneSpring Software GX7.3.1. To

identify genes enriched in NPCs and NPC-like cells, we used a data set of the whole brain of adult mice that were obtained using the same microarray platform and made available by the Gene Expression Omnibus Project on the website of the National Center for Biotechnology Information (accession number GDS592: [http://www.ncbi.nlm.nih.gov/geo/gds/gds\\_browse.cgi?gds=592](http://www.ncbi.nlm.nih.gov/geo/gds/gds_browse.cgi?gds=592)). The data was normalized to median settings across the entire probe set and samples, and transcript levels 5.0-fold or higher than those in the adult brain were taken as significant enrichment. The relative mRNA expression levels of selected genes were quantified by quantitative reverse transcriptase-chain reaction (qRT-PCR) analysis using Opticon DNA Engine (BIO-RAD). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control and statistical significance was evaluated by two-tailed unpaired t-test. The primers used are listed in Supplementary Table S3.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We are grateful to T. Kitamura, Y. Ihara, G. Oliver, I. Dobashi, M. Nagao, and M. Sugimori for reagents. We thank G. Keller and staff at the Veterinary Services Department, Matthew Kofron, Eric Brunskill, H-C. Liang, S. Smith for technical support. This study is supported by NIH/NINDS 1R01NS069893 to M.N. and K.C., Ohio Eminent Scholar Fund from the State of Ohio to M.N., AANS/CNS Research Award, Research Update in Neurosurgery and Neuroscience (RUNN) Resident Research Award and Mayfield Education and Research Foundation Grant to A.D.

## References


1. Yamanaka S. Induced Pluripotent Stem Cells: Past, Present, and Future. *Cell Stem Cell*. 2012; 10:678–684. [PubMed: 22704507]
2. Sancho-Martinez I, Izpisua Belmonte JC. Stem cells: Surf the waves of reprogramming. *Nature*. 2013; 493:310–311. [PubMed: 23325209]
3. Yang N, Ng YH, Pang ZP, Südhof TC, Wernig M. Induced Neuronal Cells: How to Make and Define a Neuron. *Cell Stem Cell*. 2011; 9:517–525. [PubMed: 22136927]
4. Leung CT, Coulombe PA, Reed RR. Contribution of olfactory neural stem cells to tissue maintenance and regeneration. *Nat. Neurosci*. 2007; 10:720–726. [PubMed: 17468753]
5. Barroca V, et al. Mouse differentiating spermatogonia can generate germinal stem cells in vivo. *Nat. Cell Biol*. 2009; 11:190–196. [PubMed: 19098901]
6. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. *Nature*. 2008; 455:627–632. [PubMed: 18754011]
7. Yechoor V, et al. Neurogenin3 is sufficient for transdetermination of hepatic progenitor cells into neo-islets in vivo but not transdifferentiation of hepatocytes. *Dev. Cell*. 2009; 16:358–373. [PubMed: 19289082]
8. Buffo A, et al. Expression pattern of the transcription factor Olig2 in response to brain injuries: Implications for neuronal repair. *Proc. Natl. Acad. Sci. USA*. 2005; 102:18183–18188. [PubMed: 16330768]
9. Ohori Y, et al. Growth Factor Treatment and Genetic Manipulation Stimulate Neurogenesis and Oligodendrogenesis by Endogenous Neural Progenitors in the Injured Adult Spinal Cord. *J. Neurosci*. 2006; 26:11948–11960. [PubMed: 17108169]
10. Torper O, Pfisterer U, Wolf DA, Pereira M, Lau S, Jakobsson J, Björklund A, Grealish S, Parmar M. Generation of induced neurons via direct conversion in vivo. *Proc. Natl. Acad. Sci. USA*. 2013; 110:7038–7043. [PubMed: 23530235]

11. Ming G-L, Song H. Adult neurogenesis in the mammalian central nervous system. *Annu. Rev. Neurosci.* 2005; 28:223–250. [PubMed: 16022595]
12. Dayer AG, Cleaver KM, Abouantoun T, Cameron HA. New GABAergic interneurons in the adult neocortex and striatum are generated from different precursors. *J. Cell Biol.* 2005; 168:415–427. [PubMed: 15684031]
13. Gould E. How widespread is adult neurogenesis in mammals? *Nat. Rev. Neurosci.* 2007; 8:481–488. [PubMed: 17514200]
14. Nakatomi H, et al. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. *Cell.* 2002; 110:429–441. [PubMed: 12202033]
15. Kernie SG, Parent JM. Forebrain Neurogenesis after Focal Ischemic and Traumatic Brain Injury. *Neurobiol Dis.* 2010; 37:267–274. [PubMed: 19909815]
16. Nakafuku, M.; Grande, A. Neurogenesis in the Damaged Mammalian Brain. In: Rubenstein, JLR.; Rakic, P., editors. *Patterning and Cell Type Specification in the Developing CNS and PNS - Comprehensive Developmental Neuroscience*. Elsevier Inc.; Maryland Heights, MO: 2013. in press
17. Yamamoto S, et al. Transcription factor expression and Notch-dependent regulation of neural progenitors in the adult rat spinal cord. *J. Neurosci.* 2001; 21:9814–9823. [PubMed: 11739589]
18. Vierbuchen T, et al. Direct conversion of fibroblasts to functional neurons by defined factors. *Nature.* 2010; 463:1035–1041. [PubMed: 20107439]
19. Pang ZP, et al. Induction of human neuronal cells by defined transcription factors. *Nature.* 2011; 476:220–223. [PubMed: 21617644]
20. Caiazzo M, et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. *Nature.* 2011; 476:224–227. [PubMed: 21725324]
21. Qiang L, et al. Directed Conversion of Alzheimer’s Disease Patient Skin Fibroblasts into Functional Neurons. *Cell.* 2011; 146:359–371. [PubMed: 21816272]
22. Son EY, Ichida JK, Wainger BJ, Toma JS, Rafuse VF. Conversion of Mouse and Human Fibroblasts into Functional Spinal Motor Neurons. *Cell Stem Cell.* 2011; 9:205–218. [PubMed: 21852222]
23. Ambasadhan R, Talantova M, Coleman R, Yuan X. Direct Reprogramming of Adult Human Fibroblasts to Functional Neurons under Defined Conditions. *Cell Stem Cell.* 2011; 9:113–118. [PubMed: 21802386]
24. Kim J, et al. Functional Integration of Dopaminergic Neurons Directly Converted from Mouse Fibroblasts. *Cell Stem Cell.* 2011; 9:413–419. [PubMed: 22019014]
25. Pfisterer U, et al. Direct conversion of human fibroblasts to dopaminergic neurons. *Proc. Natl. Acad. Sci. USA.* 2011; 108:10343–10348. [PubMed: 21646515]
26. Marro S, et al. Direct Lineage Conversion of Terminally Differentiated Hepatocytes to Functional Neurons. *Cell Stem Cell.* 2011; 9:374–382. [PubMed: 21962918]
27. Ackman JB, Siddiqi F, Walikonis RS, Loturco JJ. Fusion of Microglia with Pyramidal Neurons after Retroviral Infection. *J. Neurosci.* 2006; 26:11413–11422. [PubMed: 17079670]
28. Buffo A, et al. Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain. *Proc. Natl. Acad. Sci. USA.* 2008; 105:3581–3586. [PubMed: 18299565]
29. Shimada IS, LeComte MD, Granger JC, Quinlan NJ, Spees JL. Self-Renewal and Differentiation of Reactive Astrocyte-Derived Neural Stem/Progenitor Cells Isolated from the Cortical Peri-Infarct Area after Stroke. *J. Neurosci.* 2012; 32:7926–7940. [PubMed: 22674268]
30. Sirko S, et al. Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog glia. *Cell Stem Cell.* 2013; 12:426–439. [PubMed: 23561443]
31. Jessberger S, Toni N, Clemenson GD, Ray J, Gage FH. Directed differentiation of hippocampal stem/progenitor cells in the adult brain. *Nat. Neurosci.* 2008; 11:888–893. [PubMed: 18587391]
32. Sugimori M, et al. Combinatorial actions of patterning and HLH transcription factors in the spatiotemporal control of neurogenesis and gliogenesis in the developing spinal cord. *Development.* 2007; 134:1617–1629. [PubMed: 17344230]


33. Mattar P, Langevin LM, Markham K, Klenin N, Shivji S, Zinyk D, Schuurmans C. Basic helix-loop-helix transcription factors cooperate to specify a cortical projection neuron identity. *Mol. Cell. Biol.* 2008; 28:1456–1469. [PubMed: 18160702]
34. Parras CM, et al. Divergent functions of the proneural genes Mash1 and Ngn2 in the specification of neuronal subtype identity. *Genes. Dev.* 2002; 16:324–338. [PubMed: 11825874]
35. Shigeno T, McCulloch J, Graham DI, Mendelow AD, Teasdale GM. Pure cortical ischemia versus striatal ischemia. Circulatory, metabolic, and neuropathologic consequences. *Surg. Neurol.* 1985; 24:47–51. [PubMed: 4012559]
36. Kim J, et al. Direct reprogramming of mouse fibroblasts to neural progenitors. *Proc. Natl. Acad. Sci. USA.* 2011; 108:7838–7843. [PubMed: 21521790]
37. Lujan E, Chanda S, Ahlenius H, Südhof TC, Wernig M. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. *Proc. Natl. Acad. Sci. USA.* 2012; 109:2527–2532. [PubMed: 22308465]
38. Ring KL, et al. Direct Reprogramming of Mouse and Human Fibroblasts into Multipotent Neural Stem Cells with a Single Factor. *Cell Stem Cell.* 2012; 11:1–10. [PubMed: 22770234]
39. Thier M, et al. Direct Conversion of Fibroblasts into Stably Expandable Neural Stem Cells. *Cell Stem Cell.* 2012; 10:473–479. [PubMed: 22445518]
40. Nunes MC, et al. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. *Nat. Med.* 2003; 9:439–447. [PubMed: 12627226]
41. Ninkovic J, Götz M. Signaling in adult neurogenesis: from stem cell niche to neuronal networks. *Curr. Opin. Neurobio.* 2007; 17:338–344.
42. Puelles L, Rubenstein JLR. Forebrain gene expression domains and the evolving prosomeric model. *Trends Neurosci.* 2003; 26:469–476. [PubMed: 12948657]
43. Corti S, et al. Direct reprogramming of human astrocytes into neural stem cells and neurons. *Exp. Cell Res.* 2012; 318:1528–1541. [PubMed: 22426197]
44. Heinrich C, et al. Directing Astroglia from the Cerebral Cortex into Subtype Specific Functional Neurons. *PLoS Biol.* 2010; 8:e1000373. [PubMed: 20502524]
45. Addis RC, et al. Efficient conversion of astrocytes to functional midbrain dopaminergic neurons using a single polycistronic vector. *PLoS One.* 2011; 6:e28719. [PubMed: 22174877]
46. Karow M, et al. Reprogramming of pericyte-derived cells of the adult human brain into induced neuronal cells. *Cell Stem Cell.* 2012; 11:471–476. [PubMed: 23040476]
47. Rivers LE, et al. PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. *Nat. Neurosci.* 2008; 11:1392–1401. [PubMed: 18849983]
48. Guo F, et al. Pyramidal Neurons Are Generated from Oligodendroglial Progenitor Cells in Adult Piriform Cortex. *J. Neurosci.* 2010; 30:12036–12049. [PubMed: 20826667]
49. Ohira K, et al. Ischemia-induced neurogenesis of neocortical layer 1 progenitor cells. *Nat. Neurosci.* 2010; 13:173–179. [PubMed: 20037576]
50. Arsenijevic Y. Isolation of Multipotent Neural Precursors Residing in the Cortex of the Adult Human Brain. *Exp. Neurol.* 2001; 170:48–62. [PubMed: 11421583]
51. Russo I, Barlati S, Bosetti F. Effects of neuroinflammation on the regenerative capacity of brain stem cells. *J. Neurochem.* 2011; 116:947–956. [PubMed: 21198642]
52. Englund U, Bjorklund A, Wictorin K, Lindvall O, Kokaia M. Grafted neural stem cells develop into functional pyramidal neurons and integrate into host cortical circuitry. *Proc. Natl. Acad. Sci. USA.* 2002; 99:17089–17094. [PubMed: 12471158]
53. Yamasaki TR, et al. Neural stem cells improve memory in an inducible mouse model of neuronal loss. *J. Neurosci.* 2007; 27:11925–11933. [PubMed: 17978032]
54. Ideguchi M, Palmer TD, Recht LD, Weimann JM. Murine embryonic stem cell-derived pyramidal neurons integrate into the cerebral cortex and appropriately project axons to subcortical targets. *J. Neurosci.* 2010; 30:894–904. [PubMed: 20089898]
55. Southwell DG, Froemke RC, Alvarez-Buylla A, Stryker MP, Gandhi SP. Cortical plasticity induced by inhibitory neuron transplantation. *Science.* 2010; 327:1145–1148. [PubMed: 20185728]

56. Paxinos, G.; Watson, C. The rat brain in stereotaxic coordinates. The fourth edition. Academic Press, Inc.; San Diego, CA: 1998.
57. Olsson M, Bentlage C, Wictorin K, Campbell K, Björklund A. Extensive migration and target innervation by striatal precursors after grafting into the neonatal striatum. *Neurosci.* 1997; 79:57–78.
58. Franklin, KBJ.; Paxinos, G. The mouse brain in stereotaxic coordinate. Academic Press, Inc.; San Diego, CA: 1997.
59. Parmar M, Skogh C, Björklund A, Campbell K. Regional specification of neurosphere cultures derived from subregions of the embryonic telencephalon. *Mol. Cell. Neurosci.* 2002; 21:645–656. [PubMed: 12504597]
60. Yamamoto S, Yamamoto N, Kitamura T, Nakamura K, Nakafuku M. Proliferation of parenchymal neural progenitors in response to injury in the adult rat spinal cord. *Exp. Neurol.* 2001; 172:115–127. [PubMed: 11681845]




**Figure 1.**


Focal labeling of striatal and neocortical cells with GFP retroviruses in the adult rat brain. (a-c) Schematic diagrams illustrating the location of virus injection sites in parasagittal (a) and coronal (b,c) views. Boxes indicate the areas shown in d-k. (d-k) Distributions of GFP<sup>+</sup> cells (dashed circles and arrowheads) in the striatum (d-h) and neocortex (i-k) at DAI-3. Sections were counter-stained with methylgreen. (l-w) Co-expression of neuronal markers and GFP in virus-infected cells (arrows) in the striatum (l-s) and neocortex (t-w). Dashed lines in l, o, q, and r indicate the border of the matrix (M) and patch (P) compartments of the striatum. Arrows and arrowheads indicate GFP<sup>+</sup> cells co-expressing and non-expressing, respectively, the marker shown above each panel. The lower panels m, p, s, u, w show the co-localization of relevant markers in single cells in orthogonal views of confocal z-stack images in l, o, r, t, and v, respectively. Scale bar: d, e, f, l, 1 mm; e, g, h, j, k, 100  $\mu$ m; l, n, o, q, r, t, v, 50  $\mu$ m; m, p, s, u, w, 20  $\mu$ m. Abbreviations: Cx, neocortex; CC, corpus callosum; DG, dentate gyrus; LV, lateral ventricle; RMS, rostral migratory stream; Str, striatum; SVZ, subventricular zone.



**Figure 2.** Differential impacts of GFs and Neurog2 in neuronal induction in the adult rat striatum and neocortex. The percentages of GFP<sup>+</sup> cells expressing Dcx and NeuN in the striatum (a) and neocortex under various conditions are shown (mean ± s.d. of 3-4 animals). GFP<sup>+</sup>/Dcx<sup>+</sup> cells were examined at DAI-3 and DAI-7 in the neocortex and striatum, respectively. \*, *p* < 0.01 compared with control viruses in Student's *t* test; \$, *p* < 0.01 compared with treatment with GFs or Neurog2 viruses alone in Student's *t* test.


**Figure 3.**

Combinatorial actions of GFs and Neurog2. (a-c) The numbers of total GFP<sup>+</sup> (a), GFP<sup>+</sup>/Dcx<sup>+</sup> (b), and GFP<sup>+</sup>/NeuN<sup>+</sup> (c) cells detected at different time points after GF/virus infection (mean ± s.d., n = 3-4 animals). The number of GFP<sup>+</sup> cells in GF-untreated animals is shown in Supplementary Table S1. \*, *p* < 0.01 compared with control viruses in Student's *t* test. (d, e) The estimated numbers of GFP<sup>+</sup>/Dcx<sup>+</sup> (left) and GFP<sup>+</sup>/NeuN<sup>+</sup> (right) cells in the striatum (d) and neocortex (e) under various conditions (mean ± s.d., n = 3-4 animals). The numbers in parentheses show the percentage of GFP<sup>+</sup>/NeuN<sup>+</sup> cells at DAI-14 compared with GFP<sup>+</sup>/Dcx<sup>+</sup> cells at earlier time points. \*, *p* < 0.01 compared with control viruses in Student's *t* test; §, *p* < 0.01 compared with GFs or Neurog2 alone in Student's *t* test. nd, not detected.



**Figure 4.** Region-specific differentiation of GFP-labeled neurons in the striatum and neocortex. (a-g) Co-labeling of various neuronal markers and BrdU in GFP<sup>+</sup> cells (arrows) in the striatum. Time points after infection, types of manipulations used, and markers stained are shown above individual panels. In c-e, BrdU was administered twice each day for three days between DAI-0 and DAI-2. Dashed lines in a, b, c, and f indicate the border of the matrix (M) and patch (P) compartments of the striatum. Lower panels in a-d and g show orthogonal views of confocal z-stack images of the cells indicated by arrows. Note that the overlap of

green, red, and blue colors in c, d, and e is indicated as white color. (h-y) Region-specific phenotypes of GFP-labeled neurons in the striatum (h-p) and neocortex (q-y) at DAI-28. Arrows indicate GFP<sup>+</sup>/NeuN<sup>+</sup> neurons expressing relevant markers, whereas arrowheads indicate marker-negative GFP<sup>+</sup> and/or NeuN<sup>+</sup> cells. Images in n-p were obtained from control virus-infected animals, whereas all others were from Neurog2 virus-infected animals. (z-b2) Retrograde labeling of GFP<sup>+</sup>/NeuN<sup>+</sup> cells in the striatum by FG. FG was injected into the globus pallidus ipsilateral to the virus injection site at DAI-84, and animals were analyzed at DAI-91. z shows the distribution of FG fluorescence (white dots) in the striatum (the virus injection site in a dashed circle). a2 shows GFP<sup>+</sup>/NeuN<sup>+</sup> cells co-labeled with FG detected in the area boxed in z. b2 shows confocal images (an orthogonal view in lower panels) of a neuron boxed in a2. Scale bar: a-g, 50  $\mu$ m; h-y, 25  $\mu$ m; z, 1 mm; a2, 50  $\mu$ m; b2 and lower panels of a, b, c, d, g, and b2, 20  $\mu$ m.



**Figure 5.**

Neurogenesis in the ischemic brain. (a-n) BrdU- and GFP-labeled neurons in the adult rat striatum (a-f) and neocortex (g-n). Circles and boxes in a, d, g, and k indicate the location of virus-infected cells and the areas shown in fluorescence images, respectively. Dashed lines in b and e indicate the ventricular wall. b and e show BrdU-labeled neurons near the LV, whereas c and f show GFP-labeled neurons detected around virus-infected regions in the striatum. h and j show GFP<sup>+</sup>/NeuN<sup>+</sup> and GFP<sup>+</sup>/GABA<sup>+</sup> cells in the neocortex that received control viruses, whereas l and n show GFP<sup>+</sup>/NeuN<sup>+</sup> and GFP<sup>+</sup>/NeuN<sup>+</sup>/Glu<sup>+</sup> cells detected in Neurog2 virus-infected animals. i and m show orthogonal views of z stack confocal images of neurons indicated by arrows in h and l, respectively. (o, p) Estimated numbers of GFP<sup>+</sup>/Dcx<sup>+</sup> cells at DAI-3 (neocortex) and DAI-7 (striatum) (o), and GFP<sup>+</sup>/NeuN<sup>+</sup> cells at DAI-14 (both regions) (p) under various manipulation conditions (mean ± s.d., n = 3-4 animals). The data regarding non-ischemic animals are adopted from Fig. 3d and 3e. The numbers in parentheses show the percentage of GFP<sup>+</sup>/NeuN<sup>+</sup> cells at DAI-14 compared with GFP<sup>+</sup>/Dcx<sup>+</sup> cells at earlier time points. \*, *p* < 0.01 compared with control viruses in Student's *t* test; §, *p* < 0.01 compared with non-ischemic animals treated with GFs and Neurog2 in


Student's *t* test. nd, not detected. Scale bar: a, d, g, k, 2 mm; b, c, e, f, h, l, 50  $\mu$ m; and insets in b, c, e, f, i, j, m, n, 20  $\mu$ m.

Author Manuscript

Author Manuscript

Author Manuscript


Author Manuscript



**Figure 6.**

Neurosphere-forming cells induced by stab wound and GFs in the adult rat neocortex and striatum. (a, b) GFP<sup>+</sup> Neurospheres formed *in vitro* by cells exposed to GFs and GFP viruses *in vivo*. (c-h) Phase-contrast images (c-e) and staining for BrdU (f-h, red) of growing secondary neurospheres. Cell nuclei were stained with Hoechst 33258 (blue). (i) Frequencies of neurosphere-forming cells 14 days after tissue isolation (primary spheres, indicated as 1st) and 14 days after the first passage (secondary spheres, 2<sup>nd</sup>) (mean  $\pm$  s.d., n = 10). \*,  $p < 0.01$  in Student's  $t$  test. (j-m) Differentiation of a secondary neurosphere derived from the striatum. The cells (phase-contrast image in j) were stained for TuJ1 (k, red), GFAP (l, blue), and O4 (m, green). (n) Percentages of TuJ1<sup>+</sup>, GFAP<sup>+</sup>, and O4<sup>+</sup> cells among total cells in culture of secondary neurospheres (mean  $\pm$  s.d., n = 4). \*,  $p < 0.01$  compared to SVZ-derived cells in Student's  $t$  test. Scale bar: a, b, d-i, and k, 50  $\mu$ m.





**Figure 7.**

Differential gene expression profiles of neurosphere-forming cells derived from distinct regions of the adult mouse brain. (a) Venn diagram showing the number of genes commonly and differentially expressed in neurospheres derived from the SVZ, neocortex and striatum. Among 3,003 genes that were selected as those that gave more than a 5.0-fold higher hybridization signal with one or more of the adult neurosphere samples compared with the whole brain of adult mice. (b) Heat-map view of cluster analysis of 716 probe sets (637 genes) that showed more than a 5-fold difference in the expression level between cortical and SVZ cells (three stripes represent 3 independent cultures). Neurospheres from the dorsal and ventral forebrains (dFB and vFB) of E14.5 embryos were used for comparison. (c-i) Quantitative RT-PCR analyses of the expression of transcription factor mRNAs. The levels are normalized using GAPDH as internal control, and data are expressed as values relative to the SVZ-derived cells (designated as 1.0) (mean  $\pm$  s.d.,  $n = 3$ ). Abbreviation: dFB and vFB, dorsal and ventral embryonic forebrain culture, respectively.

**Table 1**

Neurosphere formation by virus-infected cells *in vitro*. Frequencies of primary neurosphere-forming cells among GFP<sup>+</sup> and GFP<sup>-</sup> cells within intact and GF/virus-injected tissues are quantified (mean  $\pm$  s.d., n = 3). The numbers in parenthesis are fold-increments compared to intact tissue. \*,  $p < 0.01$  compared to intact tissue in Student's *t* test; \$,  $p < 0.01$  compared to GFP<sup>-</sup> cells in Student's *t* test.

Tissue source	GFP-label	Number of neurospheres/ 103 GFP <sup>+</sup> or GFP <sup>-</sup> cells	
		Neocortex	Striatum
Intact	-	0.3 $\pm$ 0.2 (1)	0.9 $\pm$ 0.3 (1)
GF/Virus injection	-	1.1 $\pm$ 0.1 (4)*	9.9 $\pm$ 1.5 (11)*
	+	13.0 $\pm$ 3.0 (43)\$	150.0 $\pm$ 28.2 (167)\$